Type 2 Diabetes

The first iteration of Crisis Point addresses the obesity crisis in the United States and beyond, with expert interviews and discussion.

A pair of studies provide insight into the increased risk of dysglycemia among women with PCOS and the potential influence of combined oral contraceptive pills on this risk in a population-based cohort.

A multicenter case-control study of a trio of hospitals in Spain suggests the presence of diabetes was not associated with an increased risk of long-term COVID-19 symptoms.

Dr. Ponder continued his discussion on technology use in pediatric T1D care, focusing on a multidisciplinary care angle and different concepts in treatment.

Dr. Ponder discusses the importance of both clinician and patient learning about new diabetic technologies, focusing on their utility and limitations in the care process.

Analysis of data from 83k matched pairs suggests statin initiation could increase a patient's odds of diabetes progression, including need for new glucose-lowering medications and new insulin use.

Episode 4 of Crisis Point asks the question you've been waiting for, "What is blueprint to resolving the obesity crisis?"

Data show 5 of 20 patients with history of MBS in the study experienced the primary composite outcome of IMV and/or death by day 7.

An analysis of more than 650 thyroid eye disease patients is providing clinicians with insight into the most common comorbidities and risk factors associated with increased disease severity in patients with TED.

A post hoc analysis of the REWIND trial suggests women with diabetes were less likely to achieve treatment targets and receive guideline-directed medical therapies than their male counterparts.

Using data from more than 80k matched pairs of statin users and comparators, investigators from UT Southwestern Medical Center found initiation of statin therapy was associated with an increased likelihood of diabetes progression, including risk of hyperglycemia and ketoacidosis.

An analysis of survey data from nearly 800 patients with diabetes provides insight into the effects of the pandemic on diabetes management, including increased difficulty in affording diabetes medications and consulting with their diabetes care providers.

Diabetes progression included greater likelihood of insulin treatment initiation, hyperglycemia, glycemic complications, and glucose-lowering prescriptions.

Episode 3 of Crisis Point examines the regional differences in obesity, from issues with nutrition and food insecurity to the use of the phrase "food desert".

Published on September 30, the consensus report provides perspective on diagnosis and management of type 1 diabetes, including a diagnosis algorithm and insight on CGM specific to type 1 diabetes, which the writing group noted is lacking from previous guidance.

Data show SGLT2 inhibitor therapy, in comparison to GLP-1 RA therapy, was associated with slightly lower risk for myocardial infarction (MI) or stroke in patients with CVD.

Data from a recent analysis suggests patients with diabetes with the lowest levels of insulin resistance had a 40% lower risk of stroke when compared to those with the highest levels.

Research presented at the AHA's Hypertension Scientific Sessions details the increased prevalence of cardiac autonomic neuropathy and decreased survival probability associated with a non-dipping blood pressure at night.

A study from EASD 2021 suggests increased insulin resistance could help predict risk of incident stroke events among adult patients with type 2 diabetes, with results indicating lowest levels of insulin resistance were at a 40% lower risk of stroke compared to those with the highest levels.

An analysis of NHANES data presented at EASD 2021 details the effects of returning to a healthy weight among patients with obesity compared to those currently with obesity and those who always maintained a healthy weight.

In patients with T2D without prior CVD, chronic kidney disease was the single risk factor associated with highest risk of MACE.

A posthoc analysis of the REWIND trial is providing insight into the overall standard of care seen with women with diabetes and increased cardiovascular risk compared to their male counterparts with diabetes and increased cardiovascular risk.

September's endocrine month in review features news related to diabetes, polycystic ovary syndrome, warnings from the FDA and FTC, and a column from Dr. Paul Thompson.

Sotagliflozin reduced HbA1c by 0.42% and heart failure by 32% in comparison to placebo.

Episode 2 of HCPLive Crisis Point tackles the clinical aspects and potential burdens clinicians face in the pursuit of obesity care.